2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium: Meeting highlights

被引：0

作者：

Kapoor A. ^{[1
]}

Niazi T. ^{[2
]}

Noonan K. ^{[3
]}

Rendon R.A. ^{[4
]}

Alimohamed N. ^{[5
]}

Kassouf W. ^{[6
]}

Berlin A. ^{[7
]}

Chu W. ^{[8
]}

Kollmannsberger C. ^{[9
]}

So A.I. ^{[10
]}

机构：

[1] Urologic Cancer Centre for Research and Innovation (UCCRI), McMaster University, Hamilton, ON

[2] Division of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC

[3] BC Cancer, University of British Columbia, Vancouver, BC

[4] Department of Urology, Dalhousie University, Halifax, NS

[5] Tom Baker Cancer Centre, University of Calgary, Calgary, AB

[6] Department of Surgery, McGill University, Montreal, QC

[7] Cancer Digital Intelligence Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON

[8] Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON

[9] Division of Medical Oncology, University of British Columbia, BC Cancer, Vancouver, BC

[10] Department of Urological Sciences, University of British Columbia, Vancouver, BC

来源：

Yosetsu Gakkai Shi/Journal of the Japan Welding Society | 2022年 / 16卷 / 04期

关键词：

All Open Access; Bronze; Green;

D O I：

10.5489/CUAJ.7875

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：125 / 131

页数：6

共 42 条

[1] Smith MR, Hussain M, Saad F, Et al., Darolutamide and survival in metastatic, hormone-sensitive prostate cancer, N Engl J Med, (2022)
[2] Chi KN, Chowdhury S, Bjartell A, Et al., Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase 3 TITAN study, J Clin Oncol, 39, pp. 2294-2303, (2021)
[3] Chi KN, Merseburger AS, Ozguroglu M, Et al., The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN, J Clin Oncol, 40, (2022)
[4] Fizazi K, Maldonado X, Foulon S, Et al., A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1, J Clin Oncol, 39, (2021)
[5] Clarke N, Wiechno P, Alekseev B, Et al., Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomized, double-blind, placebo-controlled, phase 2 trial, Lancet Oncol, 19, pp. 975-986, (2018)
[6] Saad F, Armstrong AJ, Thiery-Vuillemin A, Et al., PROpel: Phase 3 trial of olaparib (ola) and abiraterone (abi) vs. placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), J Clin Oncol, 40, (2022)
[7] Chi KN, Rathkopf DE, Smith MR, Et al., Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations, J Clin Oncol, 40, (2022)
[8] Merseburger AS, Attard G, Boysen G, Et al., A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE, J Clin Oncol, 40, (2022)
[9] Fleshner NE, Hansen AR, Chin J, Et al., Randomized phase 2 trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP, J Clin Oncol, 40, (2022)
[10] Tagawa ST, Balar AV, Petrylak DP, Et al., TROPHY-U-01: A phase 2, open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors, J Clin Oncol, 39, pp. 2474-2485, (2021)

← 1 2 3 4 5 →